Literature DB >> 28780923

Assessment of cognitive function in patients with metastatic cancer: Are we using the right tools?

Geana Paula Kurita1, Marlene Sandvad1, Lena Lundorff2, Cibele Andrucioli De Mattos-Pimenta3, Jette Højsted4, Per Sjøgren1.   

Abstract

OBJECTIVE: This study aimed at analyzing the validity and reliability of the continuous reaction time (CRT) test, the finger-tapping test (FTT), the Digit Span Test (DST), the Trail Making Test - part B (TMTB), and the Mini-Mental State Examination (MMSE) in patients with metastatic cancer.
METHOD: Eighty adult patients and 81 healthy controls were assessed between July of 2010 and November of 2015. The neuropsychological tests were analyzed regarding construct/discriminant/criterion validity and reliability.
RESULTS: In terms of construct validity, it was not possible to estimate a model for the MMSE because of a skewed response distribution. For discriminant validity, patients were slower on two measures of the CRT (p = 0.00483, p = 0.00030) and FTT dominant hand (p = 0.00306). Regarding sensitivity and specificity, only the DST and TMTB seemed to predict cognitive deficit; however, the ROC curve areas were ≤ 0.73. In terms of criterion validity, there were few significant correlations between the tests and the sociodemographic and clinical variables, and for the most part were very weak. Reliability was deemed to be adequate for the TMTB, DST, and FTT. SIGNIFICANCE OF
RESULTS: The findings of the full validation analyses were not clear-cut. However, CRT test, DST, FTT, and TMTB demonstrated partial positive results, indicating that these tests have good potential for use in clinical settings and require further study.

Entities:  

Keywords:  Cancer; Cognition; Cognitive screening; Neuropsychological assessment; Symptom validity

Mesh:

Year:  2017        PMID: 28780923     DOI: 10.1017/S1478951517000694

Source DB:  PubMed          Journal:  Palliat Support Care        ISSN: 1478-9515


  3 in total

1.  Combining subjective and objective appraisals of cognitive dysfunction in patients with cancer: a deeper understanding of meaning and impact on suffering?

Authors:  Hanne Bess Boelsbjerg; Geana Paula Kurita; Per Sjøgren; Niels Viggo Hansen
Journal:  Support Care Cancer       Date:  2022-01-14       Impact factor: 3.603

Review 2.  Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy.

Authors:  Inger Utne; Borghild Løyland; Ellen Karine Grov; Hege Lund Rasmussen; Ann Helen Torstveit; Steven M Paul; Christine Ritchie; Kristina Lindemann; Ingvild Vistad; Claudia Rodríguez-Aranda; Christine Miaskowski
Journal:  Nurs Open       Date:  2021-12-08

Review 3.  Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors.

Authors:  Jeffrey S Wefel; Charles J Ryan; Julie Van; James C Jackson; Alicia K Morgans
Journal:  CNS Drugs       Date:  2022-05-06       Impact factor: 6.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.